AU781301B2 - Method of enhancing the efficacy of anti-tumor agents - Google Patents

Method of enhancing the efficacy of anti-tumor agents Download PDF

Info

Publication number
AU781301B2
AU781301B2 AU44863/00A AU4486300A AU781301B2 AU 781301 B2 AU781301 B2 AU 781301B2 AU 44863/00 A AU44863/00 A AU 44863/00A AU 4486300 A AU4486300 A AU 4486300A AU 781301 B2 AU781301 B2 AU 781301B2
Authority
AU
Australia
Prior art keywords
cisplatin
erythropoietin
tumor
epo
platinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU44863/00A
Other languages
English (en)
Other versions
AU4486300A (en
Inventor
M. Steven Piver
David F. Silver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of AU4486300A publication Critical patent/AU4486300A/en
Application granted granted Critical
Publication of AU781301B2 publication Critical patent/AU781301B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
AU44863/00A 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents Ceased AU781301B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/300124 1999-04-27
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
PCT/US2000/011000 WO2000064455A1 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Publications (2)

Publication Number Publication Date
AU4486300A AU4486300A (en) 2000-11-10
AU781301B2 true AU781301B2 (en) 2005-05-12

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44863/00A Ceased AU781301B2 (en) 1999-04-27 2000-04-24 Method of enhancing the efficacy of anti-tumor agents

Country Status (18)

Country Link
US (3) US6171620B1 (https=)
EP (1) EP1212068A4 (https=)
JP (1) JP2002542296A (https=)
KR (1) KR100693796B1 (https=)
CN (1) CN1188137C (https=)
AU (1) AU781301B2 (https=)
BG (1) BG64940B1 (https=)
BR (1) BR0010082A (https=)
CA (1) CA2368618C (https=)
HU (1) HUP0200840A3 (https=)
IL (1) IL146012A0 (https=)
MX (1) MXPA01010899A (https=)
NO (1) NO20015227L (https=)
NZ (1) NZ514521A (https=)
PL (1) PL350918A1 (https=)
RU (1) RU2271829C2 (https=)
WO (1) WO2000064455A1 (https=)
ZA (1) ZA200108012B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531179A (ja) 2000-04-26 2003-10-21 クイーンズ ユニバーシティ アット キングストン 悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CN101678079B (zh) 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
CL2008000905A1 (es) 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
WO2019083023A1 (ja) * 2017-10-26 2019-05-02 国立大学法人筑波大学 癌の治療に使用するための組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
RU2111750C1 (ru) * 1995-02-23 1998-05-27 Институт элементоорганических соединений РАН Модификатор для противоопухолевой терапии
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
BG64940B1 (bg) 2006-10-31
US6426094B2 (en) 2002-07-30
BR0010082A (pt) 2002-01-15
HUP0200840A2 (hu) 2002-07-29
WO2000064455A1 (en) 2000-11-02
PL350918A1 (en) 2003-02-10
JP2002542296A (ja) 2002-12-10
EP1212068A4 (en) 2007-03-14
US6620779B2 (en) 2003-09-16
NO20015227D0 (no) 2001-10-25
ZA200108012B (en) 2003-03-26
CA2368618A1 (en) 2000-11-02
CA2368618C (en) 2011-03-01
KR20020000557A (ko) 2002-01-05
CN1352561A (zh) 2002-06-05
NZ514521A (en) 2003-07-25
BG106057A (en) 2002-04-30
HUP0200840A3 (en) 2003-04-28
US20010000730A1 (en) 2001-05-03
RU2271829C2 (ru) 2006-03-20
NO20015227L (no) 2001-12-27
MXPA01010899A (es) 2003-06-24
KR100693796B1 (ko) 2007-03-12
EP1212068A1 (en) 2002-06-12
AU4486300A (en) 2000-11-10
US6171620B1 (en) 2001-01-09
US20020198153A1 (en) 2002-12-26
IL146012A0 (en) 2002-07-25
CN1188137C (zh) 2005-02-09

Similar Documents

Publication Publication Date Title
AU781301B2 (en) Method of enhancing the efficacy of anti-tumor agents
Abdel-Razeq et al. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia
Kim et al. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice
EP0224885B1 (en) Antitumor composition.
HU230273B1 (hu) Egy epotilon analóg és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére
CN108892700A (zh) 一类新型抗肿瘤化合物及其在制备抗肿瘤药物中的应用
Batist et al. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates.
JPH0296523A (ja) 白金化学療法生成物
KR101964169B1 (ko) 항종양성 백금 착체를 함유하는 항종양제 및 항종양 효과 증강제
Valley Overview of cancer‐related anemia: focus on the potential role of darbepoetin alfa
Langton-Webster et al. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line
Ford et al. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.
Gonzalez et al. Continuous intravenous infusion combination chemotherapy for head and neck squamous cell carcinoma
CN112168971B (zh) 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用
EP3965734A1 (en) Method for increasing cancer patient's haemoglobin level
CN113679720B (zh) 一种取代丁烯酰胺联合铂类化合物的药物组合物及其用途
Bellamy Fundamental concepts associated with combining cytotoxic drugs and x-irradiation
Dempke Preclinical and clinical effects of erythropoietin in the management of anaemia in patients with non-small cell lung cancer
Ellerby et al. Preliminary Report on Phase 1 Clinical Experience with Combined cis-diamminedichloride Platinum (II)(PDD) and 5-FU
Inoue et al. Antitumor activity of quinocarmycin citrate (KW-2152) against human tumor xenografts serially transplanted into nude mice
WO2024216238A2 (en) Use of beta-catenin antagonist and immunomodulator
Burtness Oncology and hematology
Shi et al. Experimental study on effect of recombinant human growth hormone combined with chemotherapy on stomach neoplasms implanted in nude mice
Benasso et al. Analysis of 16 Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck: Implications for Treatment
JP2009007255A (ja) 肺がん治療薬

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: THE NAME OF THE INVENTOR IN REGARD TO PATENT APPLICATION NUMBER 44863/00 SHOULD READ: M. STEVEN PIVER